Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma

NCT01182610 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Safety concern in a similar trial enrolling the same patient population

Conditions

Gastroesophageal Adenocarcinoma
Adenocarcinoma of the Distal Esophagus
Adenocarcinomas of the Gastroesophageal Junction
Adenocarcinoma of the Proximal Stomach

Interventions

DRUG: Panitumumab
DRUG: Paclitaxel
DRUG: Carboplatin
DRUG: 5FU

Sponsor

Accelerated Community Oncology Research Network

Collaborators

[object Object]